183 related articles for article (PubMed ID: 18022385)
21. PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.
Marshall AD; van der Ent MA; Grosveld GC
Mol Carcinog; 2012 Oct; 51(10):807-15. PubMed ID: 21882254
[TBL] [Abstract][Full Text] [Related]
22. MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cells.
Otabe O; Kikuchi K; Tsuchiya K; Katsumi Y; Yagyu S; Miyachi M; Iehara T; Hosoi H
Oncol Rep; 2017 Jan; 37(1):98-104. PubMed ID: 27840956
[TBL] [Abstract][Full Text] [Related]
23. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts.
Wang W; Slevin M; Kumar S; Kumar P
Int J Oncol; 2005 Oct; 27(4):1087-96. PubMed ID: 16142327
[TBL] [Abstract][Full Text] [Related]
24. A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR.
Galindo RL; Allport JA; Olson EN
Proc Natl Acad Sci U S A; 2006 Sep; 103(36):13439-44. PubMed ID: 16938866
[TBL] [Abstract][Full Text] [Related]
25. Pax7-FKHR transcriptional activity is enhanced by transcriptionally repressed MyoD.
Olguín HC; Patzlaff NE; Olwin BB
J Cell Biochem; 2011 May; 112(5):1410-7. PubMed ID: 21321994
[TBL] [Abstract][Full Text] [Related]
26. Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma.
Kanayama T; Miyachi M; Sugimoto Y; Yagyu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Sci Rep; 2021 Sep; 11(1):18802. PubMed ID: 34552155
[TBL] [Abstract][Full Text] [Related]
27. Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation.
Dietz KN; Miller PJ; Iyengar AS; Loupe JM; Hollenbach AD
Int J Biochem Cell Biol; 2011 Jun; 43(6):936-45. PubMed ID: 21440083
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.
Cao L; Yu Y; Bilke S; Walker RL; Mayeenuddin LH; Azorsa DO; Yang F; Pineda M; Helman LJ; Meltzer PS
Cancer Res; 2010 Aug; 70(16):6497-508. PubMed ID: 20663909
[TBL] [Abstract][Full Text] [Related]
29. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
Jothi M; Mal M; Keller C; Mal AK
Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448
[TBL] [Abstract][Full Text] [Related]
30. Alveolar rhabdomyosarcoma with neuroendocrine/neuronal differentiation: report of 3 cases.
Houreih MA; Lin AY; Eyden B; Menasce LP; Harrison J; Jones D; Folberg R; Chejfec G; Banerjee SS
Int J Surg Pathol; 2009 Apr; 17(2):135-41. PubMed ID: 18611935
[TBL] [Abstract][Full Text] [Related]
31. [Diagnosis of micrometastases of alveolar rhabdomyosarcoma].
Blizniukov OP; Petrovichev NN; Perevoshchikov AG; Poliakov VG
Arkh Patol; 2008; 70(2):36-40. PubMed ID: 18540440
[TBL] [Abstract][Full Text] [Related]
32. p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.
Hecker RM; Amstutz RA; Wachtel M; Walter D; Niggli FK; Schäfer BW
Oncogene; 2010 Jul; 29(27):3942-52. PubMed ID: 20453878
[TBL] [Abstract][Full Text] [Related]
33. PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma.
Thalhammer V; Lopez-Garcia LA; Herrero-Martin D; Hecker R; Laubscher D; Gierisch ME; Wachtel M; Bode P; Nanni P; Blank B; Koscielniak E; Schäfer BW
Cancer Res; 2015 Jan; 75(1):98-110. PubMed ID: 25398439
[TBL] [Abstract][Full Text] [Related]
34. Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells.
Zeng FY; Dong H; Cui J; Liu L; Chen T
Biochem Biophys Res Commun; 2010 Jan; 391(1):1049-55. PubMed ID: 19995556
[TBL] [Abstract][Full Text] [Related]
35. Mixed embryonal/alveolar rhabdomyosarcoma of the prostate: report of a case with molecular genetic studies and literature review.
Treetipsatit J; Kittikowit W; Zielenska M; Chaipipat M; Thorner PS; Shuangshoti S
Pediatr Dev Pathol; 2009; 12(5):383-9. PubMed ID: 19175284
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS).
Stegmaier S; Poremba C; Schaefer KL; Leuschner I; Kazanowska B; Békássy AN; Bielack SS; Klingebiel T; Koscielniak E
Pediatr Blood Cancer; 2011 Sep; 57(3):406-14. PubMed ID: 21254373
[TBL] [Abstract][Full Text] [Related]
37. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.
Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM
Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562
[TBL] [Abstract][Full Text] [Related]
38. P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma.
Bharathy N; Suriyamurthy S; Rao VK; Ow JR; Lim HJ; Chakraborty P; Vasudevan M; Dhamne CA; Chang KT; Min VL; Kundu TK; Taneja R
J Pathol; 2016 Nov; 240(3):269-281. PubMed ID: 27453350
[TBL] [Abstract][Full Text] [Related]
39. Detection of gene fusions in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction assay of archival samples.
Edwards RH; Chatten J; Xiong QB; Barr FG
Diagn Mol Pathol; 1997 Apr; 6(2):91-7. PubMed ID: 9098647
[TBL] [Abstract][Full Text] [Related]
40. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis.
Marshall AD; Lagutina I; Grosveld GC
Cancer Res; 2011 Dec; 71(24):7471-80. PubMed ID: 22037868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
